October 8, 2024 10:10 AM EDTUpdated October 11, 09:20 AM
News Briefing

Schol­ar Rock aims to raise $275M; Vin­cerx to reshuf­fle pipeline fo­cus

ENDPOINTS

Plus, news about Vi­core:

Schol­ar Rock seeks $275M in stock sale: Af­ter an­nounc­ing the suc­cess of a piv­otal clin­i­cal tri­al for its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times